Loading...
•
Mar 31, 2024
Journey Medical Q1 2024 Earnings Report
Reported solid first quarter results driven by flagship products and progress in the DFD-29 development program.
Key Takeaways
Journey Medical reported a 7% increase in total revenues for the first quarter ended March 31, 2024, reaching $13.0 million compared to $12.2 million in the first quarter of 2023. The company also made significant progress with its DFD-29 development program, with the FDA accepting the New Drug Application and assigning a PDUFA goal date of November 4, 2024.
Total revenues for Q1 2024 were $13.0 million, a 7% increase year-over-year.
Growth was driven by greater than 20% year-over-year growth in Qbrexza® and Accutane®.
The FDA accepted the New Drug Application for DFD-29 with a PDUFA goal date of November 4, 2024.
The company is focused on driving growth and profitability from its current dermatology franchise.
Forward Guidance
The company remains focused on driving growth and profitability from its current dermatology franchise and look forward to the opportunity to launch DFD-29 to benefit patients with rosacea and to leverage our existing commercial infrastructure.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...